Evidence map›Paper›PMID 30784574›Full record

ArticleImmunity2019

Live or Let Die: T Cell Survival in Cancer Immunotherapy.

Janne Ruotsalainen, Thomas Tüting

Abstract readComment
PubMed Publisher
In one paragraph

Article in Immunity, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Janne RuotsalainenLaboratory of Experimental Dermatology, Department of Dermatology, Otto-von-Guericke University, Magdeburg, Germany.
Thomas TütingLaboratory of Experimental Dermatology, Department of Dermatology, Otto-von-Guericke University, Magdeburg, Germany. Electronic address: thomas.tueting@med.ovgu.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination immune checkpoint blockade targeting CTLA-4 and PD-1 is thought to reinvigorate exhausted T cells better than monotherapies. In this issue of Immunity, Pai et al. (2019) show that, in the setting of low tumor burden, this combination regimen promotes interferon-γ-dependent T cell hyperactivation and death and thus favors tumor progression.

Indexed as

NeoplasmsT-LymphocytesCell SurvivalClonal DeletionCTLA-4 AntigenDrug Resistance, NeoplasmHumansImmunotherapyInterferon-gammaCTLA-4 AntigenInterferon-gamma

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.